Six - Months (Q 2 ) Unaudited Financial Results Period Ending 3 0 April 202 6 FY - 202 5 - 202 6 INDIES PHARMA JAMAICA LIMITED “Caring for the Nation’s Health” www.indiespharma.com

__________________________________________________________________________________________ INDIES PHARMA JAMAICA LIMITED SIX - MONTH S (Q 2 ) UNAUDITED FINANCIAL RESULTS Period E nding 3 0 April 202 6 (FY 202 5 - 2 6 QUARTER 2 ) 1 | P a g e o f 1 5 RELEASE TO SHAREHOLDERS SIX - MONTH S UNAUDITED FINANCIAL RESULTS PERIOD ENDING 3 0 APRIL 202 6 . The Board of Directors of Indies Pharma Jamaica Limited is pleased to present to our shareholders , six months of unaudited financial results for the period ending April 30, 2026 . PARTICULARS 3 Months Ended 1 st Feb to 30 Apr 2026 3 Months Ended 1 st Feb to 30 Apr 2025 Year over Year 6 Months Ended 1 st Nov to 30 Apr 2026 6 Months Ended 1 st Nov to 30 Apr 2025 Year over Year Audited Year Ended 31 Oct 2025 Revenue 285,023,525 269,996 , 025 5.6 % 564,862,973 595,825,792 - 5.2 % 1,126,320,390 Gross Profit 209,638,014 199,383,729 5.1 % 391,068,538 419,030,778 - 6.7 % 775,467,266 Profit from Operations 8 9,397,379 85,247,315 4. 9 % 144,620,282 185,956,801 - 22.2 % 262,100,358 Net Profit for the Period 62,957,598 63,772,427 - 1.3% 84,814,841 137,818,771 - 38.5 % 181,286,281 Total Comprehensive Income 62,957,598 63,772,427 - 1.3 % 84,814,045 137,818,771 - 3 8.5 % 616,286,281 Earnings per share (EPS) $ 0.0 47 $0.0 48 - 1. 6 % 0.06 4 $0.103 - 3 8. 2 % $0.14 Total Assets 3,006,403,733 2, 461 ,73 1 , 064 2 2 .1 % 3,006,403,733 2,461,731,064 22.1 % 3,055,180,150 Shareholder’s Equity 1,634,542,656 1,251,568,536 3 0.6 % 1,634,542,656 1,251,568,536 3 0.6 % 1,730,036,046 Total Liabilities 1,371,861,077 1, 210,162,529 1 3.4 % 1,371,861,077 1,210,162,529 1 3.4 % 1,325,144,104 EXECUTIVE SUMMARY : RESULTS FOR THE THREE MONTHS (Q 2 ) ENDED 3 0 APRIL 202 6 For the SECOND quarter , three months ending April 30 , 202 6 , Indies Pharma Jamaica Limited earned gross sales of J$ 285 .0 million, versus J$ 2 70 million in the prior year , an increase of 5.6 % , ❖ Gross Profit for the period increased by 5.1 % , recorded at J$ 209 million in comparison to J$ 199 million in comparison to the p rior year . ❖ Net Profit decreased by 1 . 0 % (J$6.9 million) in the current 2 nd Quarter period compared to the prior year. ❖ Earnings per share recorded a decrease of 1 . 6 % in the current 2 nd Quarter Period $0.0 47 from $0. 0 48 in comparison to the prior year .

__________________________________________________________________________________________ INDIES PHARMA JAMAICA LIMITED SIX - MONTH S (Q 2 ) UNAUDITED FINANCIAL RESULTS Period E nding 3 0 April 202 6 (FY 202 5 - 2 6 QUARTER 2 ) 2 | P a g e o f 1 5 RESULTS FOR THE SIX MONTHS (Q 2 ) ENDED 3 0 APRIL 202 6 (CON’T) Current revenue indicates a visible trajectory toward recovery following the adverse impacts of Hurricane Melissa, which suppressed projected revenue growth in the first quarter of the current fiscal year. This recovery is demonstrated by the company's imp roved second - quarter performance. Notwithstanding this sequential improvement, year - to - date revenue experienced a 5% contraction — contracting from $596 million in 2025 to $565 million as of April 30, 2026 — a decline predominantly attributable to the hurrican e - related disruptions. ❖ Gross Profit for the year decreased by 6.7 %, recorded at J$ 419 million in comparison to J$ 391 million in the prior year. ❖ Net Profit decreased by 3 8 . 5 % ( J$ 53.4 million) to $ 84 mil compared to prior year of $138 mil . ❖ Earnings per share recorded a decreased 3 8 . 2 % i n the 2 nd Quarter Period $0.0 6 4 from $0. 103 in comparison to the prior year . ❖ Total assets as of April 30, 2026, were valued at J$3.006 billion, an increase of J$544 million, or 22.1%, compared to the J$2.462 billion recorded during the corresponding period in 2025. This appreciation is due to the capital gain recognized from the re cent revaluation of the 3 - acre property designated for the construction of the Indies Pharma corporate headquarters. Furthermore, the asset growth highlights the company’s continued robust financial position. ❖ The said property has successfully obtained all necessary development and construction approvals from the relevant planning authorities. Consequent to these approvals, the asset was revalued at US$7.5 million, marking a J$435 million increase against the p revious valuation conducted in September 2021. This appreciation directly contributed to a 3 0.6 % growth in shareholders' equity, which stood at J$1.6 34 billion as of April 30, 2026, compared to J$1.251 billion as of April 30, 2025. ❖ Total liabilities were recorded in the current year Q 2 202 5 - 2 6 with a value of J$ 1. 3 72 billion compared to Q 1 202 4 - 2 5 of J $ 1. 210 b illion , an increase of 13 .4 % . This increase is due to the new NCB of J$ 1,000 billion which was used to retired Sagicor bond of J$ 805 million. 202 5 - 2 6 (Q 2 ) YTD • Total Assets J$ 3. 006 billion 22 % • Shareholders’ Equity J$ 1. 6 34 billion 31 % • Total Liabilities J $ 1 . 3 72 b illion 13% 202 4 - 2 5 ( Q 2 ) YTD • Total Assets J$ 2. 462 billion • Shareholders’ Equity J$ 1. 251 billion • Total Liabilities J$ 1. 210 b illion We express sincere gratitude to all our customers, shareholders and related stakeholders for their continued support during this difficult time caused by the recent natural disaster. W e wish everyone sustained recovery and good health. Sincerely Yours , Vishnu V. Muppuri (Mrs.) Co - founder, Executive Director & COO

__________________________________________________________________________________________ INDIES PHARMA JAMAICA LIMITED SIX - MONTH S (Q 2 ) UNAUDITED FINANCIAL RESULTS Period E nding 3 0 April 202 6 (FY 202 5 - 2 6 QUARTER 2 ) 7 | P a g e o f 1 5 INDIES PHARMA JAMAICA LIMITED Unaudited Consolidated - CASHFLOW STATEMENT For T he Six - M onths (Q 2 ) E nded 3 0 April 20 2 6 PARTICULARS Six Months Ended 3 0 Apr 202 6 Six Months Ended 30 Apr 2025 Audited Year Ended 31 st October, 202 5 J$ J$ J$ CASH FLOWS FROM OPERATING ACTIVITIES Net profit 84,396,796 137,818,771 181,286,281 Adjustment for Gain on the sale of PPE - - - Depreciation Right of Use 20,246,473 15,765,739 41,136,059 Depreciation 14,656,719 15,115,172 24,737,602 Interest expense 47,109,589 27,495,214 57,936,489 Interest Income ( 1,009,373 ) ( 635,673) ( 1,739,503 ) Interest - Right of Used Assets 626,458 2,435,077 4,015,046 Taxation 10,418,045 18,787,793 19,082,123 Unrealize exchange (gain) loss - - ( 240,635 ) Changes in operating assets and liabilities 176,444,707 216,782,092 326,213,462 Inventories 385,090 48,823,713 92,457,654 Trade Receivables ( 14,7 14,743 ) 45,301,679 (15,391,929) Trade payables ( 7 2,069,469 ) 23,953,223 121,902,898 Related Company 68,779,957 76,140,727 (67,223,620) Director ’ s a/c 109,697,269 ( 27,102,170) ( 49,961,808 ) Taxation ( Payable ) / Receivable 40,268,143 23,359,558 (4 4,182,984 ) Net Cash used in operating activities 308,790,954 407,258,822 363,813,673 CASH FLOWS FROM INVESTING ACTIVITIES Interest Received 1,009,373 635,673 1,119,722 Purchase of fixed assets ( 7,9 28 , 53 2 ) ( 45,664,246 ) ( 43,517,427 ) Right of Use Assets - - - Purchase of intangible assets ( 30, 552,385 ) ( 31,554,464 ) ( 32,979,314 ) Disposal of Investment - - - Disposal Proceed of fixed assets - - - Net cash used in investing activities ( 37, 471,544 ) ( 76,583,037 ) ( 75,377,019 ) CASH FLOWS FROM FINANCING ACTIVITIES Interest paid ( 47,736,047 ) ( 29,930,291 ) ( 6 1,951,535 ) Short term Borrowing (2,199,714) - 1,453,442 Loan received - 459,629 1,000,000,000 Dividend Pad (179,892,448) (179,892,448) (1 79,892,418 ) Loan Repayment - - (805,000,000) Lease liabilities ( 12,456,145 ) ( 22,641,096_ ) (4 3,314,862 ) Net cash provided by financing Activities ( 2 42,284,354 ) ( 232,004,207 ) (88,705,373) - This section of the page is left blank intentionally -

__________________________________________________________________________________________ INDIES PHARMA JAMAICA LIMITED SIX - MONTH S (Q 2 ) UNAUDITED FINANCIAL RESULTS Period E nding 3 0 April 202 6 (FY 202 5 - 2 6 QUARTER 2 ) 9 | P a g e o f 1 5 INDIES PHARMA JAMAICA LIMITED Notes to the Unaudited Financial Statements For The Six - Months (Q2) Ended 30 April 2026 1. IDENTIFICATION AND ACTIVITIES INDIES PHARMA JAMAICA LIMITED is a limited liability company incorporated under the laws of Jamaica on the 09th day of December 2003 and domiciled in Jamaica. The registered office of the company is Unit #5 Montego Bay Trade Centre, Catherine Hall, Montego Bay, St James. The principal activity of the company is the distribution and retailing of pharmaceutical and auxiliary products. The company by special resolution dated 4th November 2014 converted from a private to a public company. The Company’s shares were listed on the Junior Market of the Jamaica Stock Exchange on August 15th, 2018. 2. BASIS OF PREPARATION These condensed unaudited interim financial statements for the ‘ Six Months ended April 3 0 , 202 5 ’ have been prepared by IAS 34 – Interim Financial Reporting. The interim financial statements should be read in conjunction with the audited financial statements ended 31 st October 202 4 (Q 4 ) which have been prepared by The International Financial Reporting Standards (IFRS) and their interpretations adopted by the International Accounting Standards Board (IASB). The accounting policies are consistent with those applied to the audited financial statements for the year ended 31 October 202 5 . The financial statements are expressed in Jamaican Dollars. IFRS 16 ‘Leases’ The company has adopted IFRS 16 from 1 November 2019 and has not restated comparatives for the prior reporting period as submitted under the specific transitional provisions in the standard in applying the simplified transition approach. The reclassificati ons and the adjustments arising from the new leasing rules are therefore recognized in the opening statement of financial position on 1 November 2019. IFRS 16 introduces a single lease accounting model for lessees. It requires lessees to recognize a lease liability reflecting future lease payments and a “right - of - use - asset’ for virtually all lease contracts. The standard includes an optional exemption fo r certain short - term leases of low - value assets. For lessors , the accounting stays almost the same. Effective 1 November 2019, leases are recognized as a “ right - of - use - asset” and a corresponding liability at the date at which the leased asset is available for use by the company. Each lease payment is allocated between the liability and finance costs . The finance cost is charged to profit or loss over the lease period to produce a constant periodic interest rate on the remaining balance of the liability for each period. The right - of - use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight - line basis. Assets and liabilities arising from a lease are initially measured on a present - value basis .

Source: Original PDF